611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Excess Weight May Raise Rosacea RiskDecline in Antibiotic Use in Livestock Isn't Enough, Critics SayCould a Hot Cup of Tea Preserve Your Vision?Breathing Retraining Beneficial in Patients With AsthmaZika Babies Facing Increasing Health Problems With AgeHealth Tip: Dental Association Supports Fluoridated WaterAnother Legacy of Terror Attacks: MigrainesRain May Not Cause Achy Joints After AllDisrupted Sleep Linked to Increased Amyloid-β ProductionAtherosclerosis ID'd in Many Without CV Risk FactorsArtificial Intelligence Promising for CA, Retinopathy DiagnosesFirst Drug Approved for Rare Condition That Inflames Blood VesselsProtecting Your Health From Wildfire SmokeHealth Tip: Recognize Warning Signs of HypothermiaNew Hope for Kids With Multiple Food AllergiesFew Patients, Providers Discuss Costs of Glaucoma Medicationsβ-Cell Sensitivity to Glucose Impaired After Gastric BypassHow to Perk Up the Holidays for Hospital PatientsVigorous Exercise May Help Slow Parkinson's DiseaseIf Mom Has Rheumatoid Arthritis, Baby May Develop It, TooNew Gene Therapy May Be Cure for 'Bubble Boy' DiseaseAnother Gene Therapy Breakthrough Against HemophiliaPrenatal Sugar Intake May Increase Asthma Risk in OffspringObesity May Be Tied to Higher Rosacea Risk in WomenGot Scabies? Here's What to DoAre Women With Parkinson's at a Disadvantage?Bariatric Surgery Alters Liver Fatty Acid MetabolismORBIT Bleeding Risk Score Performs Best in A-FibHealth Tip: Prevent the Spread of NorovirusAre Good Kidneys Going to Waste?Metabolic Risk Factors Linked to Severe Liver DiseaseImpaired White Matter Integrity for Depression in Parkinson'sHave Eczema? No Need for Bleach Baths, Study SuggestsPowerful Clot-Busting Drugs Not Useful After Leg Blockages: StudyComing Soon: A Gel That Could Help Save Soldiers' EyesGene Therapy May Allow Hemophilia Patients to Go Without MedsThyroidectomy-Specific Quality Improvement Measures ID'dPatients OK With Fewer Opioids After Gallbladder SurgeryShhhh! Patients Are SleepingDiagnostic Mutations ID'd in Chronic Kidney Disease PatientsAntithrombotics Deemed Safe in Carpal Tunnel Release SurgeryLink Between Diabetes, Antibiotic Use Called Into QuestionHealth Tip: Diagnosing PneumoniaNoisy Commutes Could Cause Long-Lasting DamageThe Buzz on How Flies Spread DiseaseRisk of Surgical Complications Up for Overlapping Hip SurgeryOral Microbiome Composition Linked to Esophageal Cancer RiskSmartphone Pics Help Docs ID Kids' Skin ConditionEven Non-Heart Surgery May Harm Your HeartCan Scrotal Vein Condition Hike Heart Risks?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Lower Risk of Gastrointestinal Bleeding for Apixaban


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, according to a study published in the April issue of Gastroenterology.

Neena S. Abraham, M.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues conducted a retrospective study using administrative claims data of privately insured individuals and Medicare Advantage enrollees. Three propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban were created. Data were compared on rivaroxaban versus dabigatran for 31,574 patients; for apixaban versus dabigatran for 13,084 patients; and for apixaban versus rivaroxaban for 13,130 patients.

The researchers found that GI bleeding occurred more often in patients given rivaroxaban versus dabigatran (hazard ratio, 1.2). The risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban (hazard ratios, 0.39 and 0.33, respectively). For apixaban and rivaroxaban, the median times to gastrointestinal bleeding were <90 days, while for dabigatran, the median time was <120 days.

"In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile " the authors write.

Abstract
Full Text
Editorial